DORIAN evolving neuroimaging

status of the initiative







DORIAN (Diagnosis ORlented ANalysis)

DORIAN delivers a fast and reliable tool for the quantification of medical imaging to support the early and differential diagnosis of neurodegenerative disorders. It provides clinicians and researchers with state-of-the-art robust, rater-independent and reproducible quantitative biomarkers to better evaluate the β -amyloid load in brain tissue, complementing their ability to write an informed medical report and improve on the early detection and diagnosis of neurodegenerative diseases.

Dorian recent & next timepoints

- > Meet in Italy 4 Lifesciences
- > Smartcup Regione Liguria | UNIGE StartCup
- > Premio Nazionale per l'innovazione
- > BIOGEN meeting
- > First business contract
- > Fondazione spin-off
- > HoSession @ Nucl. Med. school in Neurology
- > HoSession @ EANM | Talk @ EADC



Nuclear Medicine



Dorian system



- Client app
- Back-end server
- Computing




(monitoring) > Second opinion for ELM same REARCE. ELMs and draw interval 22 REAR R75 areas R752206. R78 and draw interval 22 R742 early diagnosis of Report 2 Alzheimer' disease EDZENO > GDPR compliant _ $\nabla \Delta X \Delta \nabla$ > 20 min. / analysis remote analysis connect / upload get results (farm / cloud)




Desktop client





Desktop client



Collaboration with AIMN

DORIAN - BRAIN SOFTWARE PROJECT

 \rightarrow Host (& maintain) and give access to multiple research tools (amyloid-PET, FDG-PET, DATSPECT, MRI?)

 \rightarrow Collect metadata / images into the first italian (normative)-database of amyloid PET images

 \rightarrow Minimum image quality requirements (harmonization of acq. protocols)

 \rightarrow Results visualization discussion




Metadata for this exam	
Patient Name	
Birth Date	27/01/2020
Education	0.30
Patient Gender	OF OM OU
Initial subjective symptomatology	Memory Language Visuospatial Executive Apraxy Attention ☑ Other (specify)
Pre-PET clinical suspicion	MCI 🗌 PossAD 🗌 ProbAD (85%+) 🗌 FTLD 🗌 VAD 📄 DLB 🜌 Other (non-specified dementio)
Comorbidity	Diabetes 🗌 Cardiopathy 🗌 Arterious hypertension 🗌 Major internal organ disease 🗌 Depression 🗹 Non-specified
Evidence of atrophy (MRI)	○ Not avail. ○ No ♥ Yes (specify)
Evidence of hypometaboism (FDGPET)	O Not avaiL ○ No ○ Yes
MMSE	0.30
Amyloid-PET tracer	Florbetopir \$
Notes	




Dorian






"Standard" atlas - cortical 25 contralateral + 1 regions



Data-driven atlas


IN PROGRESS..

DORIAN evolving neuroimaging



A template for each amyloid (^{18}F) tracer, built from EADC PET-2 initiative data (~50 amyloid neg / pos).

ANTS iterative registration (multivariate template construction, 20851191). Registered on MNI by ADNI temolate from flarhetaair



flutemetamol

 \rightarrow will be submitted as a paper


Registration & quality check



 \rightarrow ANTS: PET / PET + CT (antsRegistrationSyN), CT on CT template (<u>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3376197/</u>) and transform applied to corresponding PET

- 1. Multiscale registration
- 2. Rigid + affine
- 3. MNI atlases / parcellations warped to target PET

 \rightarrow Convolutional network classifier trained on good / bad $\,$ registration





DORIAN evolving neuroimaging

Thank you